The FDA will decide on whether to approve the first oral formulation of a GLP-1 (25 mg/d semaglutide) for chronic weight management by the end of the year.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/oral-glp-1-will-change-and-enhance-obesity-treatment-2025a1000pg8?src=rss
Author :
Publish date : 2025-09-24 07:00:00
Copyright for syndicated content belongs to the linked Source.